Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses. Multiple strategies are being explored to improve efficacy by concurrent inhibition of other functionally relevant receptor tyrosine kinases (RTK). XL880 (foretinib, GSK1363089) and XL184 (cabozantinib) are small-molecule inhibitors that potently block multiple RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor invasion and metastasis. This study compared the cellular effects of XL880 and XL184 with those of an RTK inhibitor (XL999) that blocks VEGFR but not c-Met. Treatment of RIP-Tag2 mice with XL999 resulted in 43% reduction in vascularity of spontaneous pancreatic islet tumors over 7 days, but treatment with XL880 or XL184 eliminated approximately 80% of the tumor vasculature, reduced pericytes and empty basement membrane sleeves, caused widespread intratumoral hypoxia and tumor cell apoptosis, and slowed regrowth of the tumor vasculature after drug withdrawal. Importantly, XL880 and XL184 also decreased invasiveness of primary tumors and reduced metastasis. Overall, these findings indicate that inhibition of c-Met and functionally related kinases amplifies the effects of VEGFR blockade and leads to rapid, robust, and progressive regression of tumor vasculature, increased intratumoral hypoxia and apoptosis, and reduced tumor invasiveness and metastasis. Cancer Res; 71(14); 1-11. Ó2011 AACR.
Introduction
Inhibitors of VEGF signaling block VEGF-driven angiogenesis, prune VEGF-dependent blood vessels, and normalize vessels that do not regress (1) (2) (3) (4) . VEGF inhibitors can also promote tumor invasion and metastasis in some preclinical models (5, 6) , but the underlying mechanism is still unclear (7, 8) . Treatment of cancer patients with VEGF inhibitors can slow tumor growth and in some cases prolong survival, but resistance eventually develops and the disease progresses through growth of residual primary tumor or metastases (9) (10) (11) (12) . Inhibitors that target other pathways, such as those involved in tumor invasiveness, are therefore being developed (13, 14) .
Hepatocyte growth factor (HGF, scatter factor), through its HGF receptor (HGFR) c-Met, is a potent motility factor and mitogen (15) (16) (17) (18) . HGF and c-Met are upregulated in many human cancers and contribute to tumor growth, angiogenesis, invasiveness, and metastasis (19, 20) . Inhibition of the HGF/ c-Met pathway can reduce tumor growth, angiogenesis, and metastasis in preclinical models (21) (22) (23) (24) .
c-Met expression is increased by hypoxia through activation of hypoxia inducible factor-1a (HIF-1a) and contributes to the aggressiveness of hypoxic tumors (25) . HIF-1a-induced c-Met expression could be triggered by vascular pruning caused by VEGF inhibitors and could select for migratory, invasive tumor cells and predispose spread by metastasis (26) . The strategic roles of VEGF receptor (VEGFR) and c-Met signaling in tumor angiogenesis, invasion, and metastasis make these receptors attractive therapeutic targets (16) (17) (18) 27) .
We examined the effects of 2 small-molecule receptor tyrosine kinase (RTK) inhibitors, XL880 (foretinib, GSK1363089) and XL184 (cabozantinib) , that block phosphorylation of c-Met and VEGFR at nanomolar or subnanomolar concentrations (27) (28) (29) to assess the interaction of these receptors in tumors. As set out in Table 1 , both XL880 and XL184 block c-Met and VEGFR-2. In addition, XL880 inhibits AXL, Tie2, KIT, FLT3, platelet-derived growth factor receptor (PDGFR), and RON (27, 30, 31) , and XL184 inhibits AXL, Tie2, KIT, FLT3, and RET but not PDGFR or RON (28, 29, 32) . The lack of overlap of PDGFR and RON makes these receptors unlikely to explain the mutual effects of XL880 and XL184 on tumors.
The effects of a third RTK inhibitor, XL999, which blocks VEGFR, PDGFR, fibroblast growth factor receptor (FGFR), FLT3, KIT, and AXL, was used for comparison because it does not block c-Met but does block many other targets of XL880 and XL184 (33, 34) . Spontaneous pancreatic islet tumors in RIP-Tag2 transgenic mice were used as a model (4, 35, 36) , and the abundance, cellular composition, and receptor expression of tumor blood vessels, intratumoral hypoxia, and measures of tumor aggressiveness were used as readouts.
Our studies revealed that XL880 or XL184, but not XL999, led to rapid, widespread, and progressive regression of tumor vasculature, extensive hypoxia, and apoptosis of tumor cells and decreased tumor aggressiveness.
Materials and Methods

Animals
RIP-Tag2 mice in a C57BL/6 background were used as the tumor model (35) . All experiments were approved by the University of California, San Francisco, Institutional Animal Care and Use Committee.
Treatments
RIP-Tag2 mice were 10-week-olds at the onset of treatment, unless otherwise indicated. XL880 (foretinib, GSK1363089), XL184 (cabozantinib), and XL999 were suspended at a concentration of 5 mg/mL in sterile saline or water and administered by gavage, daily for 7 days (see Supplementary Materials and Methods).
Detection of functional blood vessels and hypoxia
Functional blood vessels in tumors were identified and marked by fluorescein isothiocyanate (FITC)-labeled Lycopersicon esculentum lectin (LEA; 1 mg/mL, 100 mL; Vector Laboratories), injected via a tail vein (i.v.) 2 minutes before the perfusion of fixative (4) . Hypoxic regions of tumors were identified by pimonidazole hydrochloride (60 mg/kg, 2.5 mL/g of mouse body weight; Hypoxyprobe Plus Kit HP2; Chemicon) injected i.v. 1 hour before the perfusion (5).
Tissue fixation and immunohistochemistry
Mice were perfused through the heart with paraformaldehyde fixative (4, 36) . Cryostat sections (80 mm in thickness) were stained with combinations of the antibodies (see Supplementary Materials and Methods).
Imaging and analysis
Specimens were examined with a Zeiss Axiophot fluorescence microscope and a Zeiss LSM 510 laser scanning confocal microscope. Area densities of endothelial cells, pericytes, basement membrane, apoptotic cells, and hypoxic regions were calculated from digital fluorescence microscopic images, using an empirically determined threshold value of 30 to 50 (4, 36) . Intensity of VEGFR-2, VEGFR-3, and E-cadherin immunofluorescence was measured (4, 36) . Metastases of RIP-Tag2 tumors were identified in sections of liver stained for SV40 Tantigen. Vascularity of the trachea was expressed as the average number of capillaries that crossed cartilage rings (10 rings/mouse, 4-5 mice/group; ref. 37).
Tumor size and Invasion index
The size of tumors in the pancreas from RIP-Tag2 mice treated with vehicle, XL880, or XL184 for 7 days (5 mice/group) was assessed in 80-mm sections stained for insulin or SV40 Tantigen and expressed as the sectional area of tumor (4) .
Invasion index was measured using ImageJ on fluorescence microscopic images (5Â objective, 1Â Optovar) of 80-mm sections of pancreas stained for insulin or SV40 T-antigen (red) and amylase (green channel). The red channel of RGB images was converted to 8-bit gray scale, and the tumor border was outlined using the freehand tool. Regions outside the tumor were filled black. A threshold in the range of 0 to 255 was applied to include all tumor cells and then the image was converted to binary. Invasion index (values !1.0) was calculated from the area and perimeter of the tumor by the formula: 1/(4p Â area/perimeter 2 ), where a circle has a value of 1.0. The median Invasion index was calculated for all tumors in each mouse (10-21 tumors/mouse). The mean Invasion index for each group was calculated from the median value for each mouse (4 mice/group).
Immunoprecipitation and quantitative reverse transcriptase-PCR
Immunoprecipitation and quantitative reverse transcriptase-PCR analysis were carried out as described in Supplementary Materials and Methods.
Statistics
Values are expressed as means AE SE (4-6 mice/group). The significance of differences between groups was assessed by 
Results
Massive regression of tumor vessels after XL880 or XL184 treatment Blood vessels in RIP- Tag2 XL999, which inhibits VEGFR but not c-Met, reduced the vascularity of RIP-Tag2 tumors, but the magnitude of the reduction at 7 days (43%) was significantly less than after XL880 (80%) or XL184 (77%) treatment [ Fig. 1D (i) ], and the surviving blood vessels were different. After XL880 or XL184 treatment for 7 days or longer, many remaining tumor vessels were narrow, variable in diameter, and appeared fragmented [ Fig. 1D (ii) ]. In contrast, most tumor vessels present after XL999 treatment for 7 days were larger, more uniform in caliber ("normalized"), and had less branching and fewer sprouts than present under baseline conditions [ Fig. 1D (iii) ].
Because of evidence that some capillaries of normal organs regress after VEGF inhibition (4, 38, 39), we investigated this Figure 1 . Effects of XL880, XL184, and XL999 on tumor vessels. Fluorescence micrographs compare the vasculature of RIPTag2 tumors stained for CD31 immunoreactivity. A, i and ii, vascularity is conspicuously greater after vehicle than after XL880 treatment (60 mg/kg) for 7 days. A, iii, dose-response of tumor vessel regression after XL880 treatment for 7 days. B, i-iii, no reduction of vascularity at 6 hours after XL880 treatment (40 mg/kg) but conspicuous reductions after 1 day or 14 days. B, iv, time course of reduction in tumor vascularity after XL880 treatment. C, i and ii, reduction in vascularity after XL184 treatment (30 mg/kg) for 7 days. C, iii, doseresponse after XL184 treatment for 7 days. D, i, smaller reduction in vascularity after XL999 than after XL880 or XL184 treatment. D, ii, narrow, irregular, or fragmented tumor vessels (arrows) still present after XL880 or XL184 treatment for 7 days. D, iii, larger and less tortuous tumor vessels (arrows) remain after XL999 treatment for 7 days. *, P < 0.001 versus vehicle. †, P < 0.001 versus XL880 and XL184. Scale bar, 120 mm (A-C); 30 mm (D).
effect of XL880 and found consistent reductions in the number of capillaries in the trachea, thyroid, choriocapillaris of the eye, and jejunum ( Supplementary Fig. S1 ).
Reduction in VEGFR-2 and VEGFR-3
Strong and widespread VEGFR-2 immunoreactivity highlighted the dense vascularity of RIP-Tag2 tumors under baseline conditions [ Fig. 2A (i) ] but was conspicuously reduced after XL880 treatment [ Fig. 2A (ii) ]. Overall, VEGFR-2 immunoreactivity was reduced by 93% after the 7-day treatment [ Fig. 2A (iii) ]. The speed of the change was evident by the 86% reduction in the expression of VEGFR-2 mRNA after only 1 day [ Fig. 2A (iv) ].
VEGFR-3 immunoreactivity was also strong and widespread on tumor vessels and was sharply reduced by XL880 treatment for 7 days [ Type IV collagen immunoreactivity largely matched the CD31 staining of blood vessels in tumors at baseline [ Fig. 3C (i and ii) ]. The amount of type IV collagen was reduced after XL880 treatment for 7 days [ Fig. 3C (iii) ] but not as much as CD31 staining [ Fig. 3C (iv) ]. Measurements showed a 52% reduction in type IV collagen compared with the 80% reduction in CD31 [ Fig. 3D (i) ].
The number of empty basement membrane sleeves was reflected by the discrepancy between the loss of endothelial cells and the loss of basement membrane [ Fig. 3D (i) ]. After XL880 treatment for 7 days, about 20% of the original amount of basement membrane was on surviving tumor vessels, 28% was in the form of empty sleeves, and 52% was lost. Vascular basement membrane was similarly reduced after XL184 treatment [ Fig. 3D (ii and iii) ].
Regrowth of tumor vasculature
Stopping XL880 after treatment for 7 days was followed by partial regrowth of the tumor vasculature over the subsequent 7 days, but tumor vascularity did not return to the baseline [ Supplementary Fig. S2A (i-iv) ]. With 77% reduction in vascularity after 7-day treatment as a reference, recovery was 22% (58% below baseline) at 2 days and was 51% (29% below baseline) at 7 days [ Supplementary Fig. S2B (i) ]. Consistent with continuing regrowth, endothelial cell sprouts were still present at 7 days [ Supplementary Fig. S2B (ii) ].
Recovery of the intensity of VEGFR-2 immunofluorescence of tumor vessels was not similarly delayed. Brightness of VEGFR-2 immunofluorescence was 54% less than baseline after XL880 treatment for 7 days but was only 21% less at 2 days and was back to baseline at 7 days [ Supplementary  Fig. S2B (iii) ]. Similarly, hypoxic regions of tumors marked by pimonidazole staining rapidly decreased after XL880 treatment was withdrawn and were not present at 7 days after treatment ended [ Supplementary Fig. S2C (i-iv) ].
Distribution of c-Met in tumors
Under baseline conditions, the pattern of c-Met immunoreactivity was largely vascular Pixels where c-Met immunoreactivity colocalized with CD31 decreased by at least half after XL880 or XL184 treatment, suggestive of a preferential effect on endothelial cells [ Fig. 4D (ii) ]. This was not found after XL999 treatment.
Overall, c-Met protein in tumors assessed by immunoprecipitation was slightly less after XL184 treatment, but phosphorylated c-Met was markedly reduced after XL184 treatment for 7 days [ Fig. 4D (iii) ]. Neither of them changed after XL999 treatment [ Fig. 4D (iii) ].
Intratumoral hypoxia and apoptosis
Hypoxic regions marked by pimonidazole staining were sparse or absent in tumors of 10-or 11-week old RIP-Tag2 mice treated with vehicle [ Fig. 5A (i) ] but were abundant and conspicuous in tumors after XL880 or XL184 treatment for 7 days [Fig. 5A (ii and iii) ]. Surface plots highlighted the difference between negligible pimonidazole immunofluorescence in vehicle-treated tumors and the strong, widespread staining after XL880 treatment [ Fig. 5B (i) ]. Pimonidazole staining was increased about 100-fold, from 11% of tumor area after XL880 treatment and 9% after XL184 treatment, compared with the baseline value of only 0.1% [ Fig. 5B (ii)].
After XL880 or XL184 treatment, most pimonidazole staining was in regions of tumors that were avascular or had narrowed blood vessels 
Tumor aggressiveness
As indices of aggressiveness of RIP-Tag2 tumors, we examined tumor shape, E-cadherin staining, size, and metastasis to the liver. The contour of the tumor perimeter was assessed in sections stained for insulin or SV40 T-antigen in tumor cells and amylase in the surrounding acinar pancreas. Vehicletreated tumors had irregular borders [ Fig. 6A (i and ii) ], but tumors treated with XL880 for 14 days had a smooth contour and distinct margin with the neighboring acinar pancreas [ Fig. 6A (iii and iv) ]. The irregularity of the tumor border, quantified as the Invasion index, was significantly less (value ¼ 3.4) after XL880 treatment for 14 days than after vehicle treatment [value ¼ 5.4; Fig. 6B (i-iii) ].
E-cadherin immunoreactivity of tumor cells, as an indicator of epithelial-mesenchymal transition status (40) , was faint to absent under baseline conditions [ Supplementary Fig. S2D (i) ] but was stronger after XL880 or XL184 treatment for 7 days [ Supplementary Fig. S2D (ii and iii) ]. The mean intensity of Ecadherin immunofluorescence increased from 32 in vehicletreated tumors to 41 after XL880 treatment and 46 after XL184 treatment for 7 days [ Supplementary Fig. S2D (iv) ]. The acinar pancreas and pancreatic ducts had strong E-cadherin immunoreactivity under all conditions.
Tumors in RIP-Tag2 mice treated for 7 days, beginning at age 10 weeks, were 40% smaller after XL880 treatment and 35% smaller after XL184 treatment than corresponding values for vehicle [ Fig. 6C (i) ].
Tumor cells, identified by SV40 T-antigen immunofluorescence, were scattered in histologic sections of liver from 3 of 4 RIP-Tag2 mice treated with vehicle for 14 days [ Fig. 6C (ii) ], but none were found in livers of 4 mice treated with XL880 for the same period [ Fig. 6C (iii) ].
To determine whether RIP-Tag2 tumors become more invasive after XL880 is withdrawn, we treated mice with XL880 for 7 days, from age 10 to 11 weeks, and then studied them 7 or 14 days later. The border of tumors was irregular at baseline but was much smoother after XL880 treatment for 7 days [ Fig. 6D (i and ii) ]. At 7 days after treatment ended, the tumor border was still smooth, but small groups of tumor cells projected into the surrounding acinar pancreas [ Fig. 6D (iii) ]. At 14 days, tumors had irregular borders similar to but not greater than those at baseline [ Fig. 6D (i and iv) ]. Measurements of Invasion index reflected these changes [ Fig. 6D (v) ].
Discussion
The overall goal of this study was to determine the cellular effects of 2 small-molecule RTK inhibitors, XL880 and XL184, that block key signaling pathways involved in angiogenesis and tumor invasiveness. Both inhibitors target VEGFR and c-Met at low nanomolar or subnanomolar concentrations, together with several other RTKs, and both had rapid, robust, profound, and largely similar cellular effects on blood vessels and tumor cells of RIP-Tag2 tumors. These effects differed qualitatively and quantitatively from those found after treatment with XL999, an RTK inhibitor that does not target c-Met but does block VEGFR plus multiple other receptors blocked by XL880 and XL184.
Treatment with XL880 or XL184 led to rapid and severe changes in tumor blood vessels, which were greater than after XL999 over a similar dosage range or after other VEGF inhibitors (4, 36, 41) . VEGFR-2 and VEGFR-3 proteins and their respective mRNA expression were reduced even more than corresponding values for CD31, consistent with dual effects of vessel regression and downregulation of expression on the remaining tumor vessels (4, 36) .
Selective inhibition of VEGF signaling causes regression of some tumor vessels, but those that remain tend to be more normal (3, 4) , which were confirmed after XL999. However, surviving tumor vessels were qualitatively different after XL880 or XL184 treatment, which were narrow, fragmented, and not stained by i.v. FITC-LEA, suggestive of continuing regression (4, 36, 41) . The tumor vascularity continued to decrease during the second week of XL880 treatment. This progressive change differs from vascular regression due to many selective VEGF inhibitors, which tends to plateau after a week or so as tumor vessels normalize (3, 4) .
Basement membrane sleeves and pericytes were decreased after treatment with XL880 or XL184. Some reduction was also found with XL999, as has been reported for other VEGF (4, 36, 41) , but the decrease was less. Basement membrane sleeves depend in part on the viability of the associated endothelial cells and/or pericytes, but they were not lost proportionally: endothelial cells were reduced by 80%, pericytes by 71%, and basement membrane by only 52%.
Tumor vessels rapidly regrow after withdrawal of VEGF inhibitors (36) . Tumor vessels also regrew after withdrawal of XL880 or XL184, but the regrowth was slowed. Although the mechanism is uncertain, one factor for the reduced vascular regrowth after XL880 or XL184 treatment may be the greater loss of pericytes and basement membrane sleeves that provide a scaffold for regrowing blood vessels (36) .
To better understand the robust effects of XL880 and XL184 on blood vessels in RIP-Tag2 tumors, we examined the amount and distribution of c-Met immunoreactivity.
Strong staining for c-Met was consistently found in some tumor vessels at baseline. Colocalization with CD31 indicated the vascular staining of c-Met was restricted to endothelial cells. In addition, some tumor cells marked by SV40 T-antigen had faint c-Met immunoreactivity. Vascular staining for c-Met was conspicuously less after XL880 or XL184 treatment but was unchanged after XL999 treatment. Consistent with this finding, total c-Met and phosphorylated c-Met, assessed by immunoprecipitation, were both reduced after XL184 treatment, but neither was significantly reduced after XL999 treatment. On the basis of intensity of c-Met immunoreactivity, vascular endothelial cells probably made a significant contribution to the signal in the immunoblots and were targets of XL880 and XL184, but the presence of weak staining in tumor cells indicates that c-Met blockade is The robust effects of XL880 and XL184 on RIP-Tag2 tumors were not limited to tumor vessels. Intratumoral hypoxia and tumor cell apoptosis were also widespread. Induction of hypoxia and apoptosis was probably due to the extensive and progressive pruning of tumor vessels without vessel normalization. The association of pimonidazole staining with regions of tumor that had few or no blood vessels is consistent with this interpretation.
Invasiveness, which is a typical feature of aggressive tumors (42, 43) , increases in some preclinical models after inhibition of VEGF (5, 6, 44, 45) . Treatment with XL880 resulted in smaller and less invasive tumors in RIP-Tag2 mice, and, importantly, recovery of tumor invasiveness was slowed and did not rebound at an exaggerated rate during the first 2 weeks after XL880 was withdrawn.
The (46) (47) (48) (49) , this is unlikely to be the main target because XL880, XL184, and XL999 block AXL about equally, with IC 50 values in the range of 4.6 to 11 nmol/L.
The kinase profiles of XL880, XL184, and XL999 had differences in addition to c-Met, and drug efficacy is also influenced by in vivo absorption, stability, clearance, and other chemical properties that influence pharmacokinetics and pharmacodynamics. Therefore, confirmation of essential or exclusive roles of inhibition of c-Met and VEGFR in the anti-invasive effects of XL880 and XL184 will require the use of more selective inhibitors, comparison of drug actions after genetic deletion of c-Met, or other strategies that target these signaling pathways without impacting other receptors.
In conclusion, we found that XL880 and XL184 caused rapid and extensive regression of endothelial cells and pericytes of blood vessels in RIP-Tag2 tumors. Regression of the tumor vasculature was widespread, progressive, and accompanied by extensive intratumoral hypoxia and apoptosis of tumor cells. The treated tumors were smaller, less invasive, and accompanied by fewer liver metastases. The findings are consistent with the distinctive antitumoral actions of XL880 and XL184 resulting from inhibition of VEGFR and c-Met together. However, inhibition of other receptors and chemical properties that influence pharmacokinetics and pharmacodynamics could also contribute. Careful assessment using strategies for selective inhibition or knockdown of individual receptors or pathways will be necessary to determine whether inhibition of VEGFR and c-Met is necessary and sufficient to reproduce all of the robust effects of XL880 and XL184 on tumors.
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